How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

27,797 results for

Topical Corticosteroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Topical corticosteroids effective for nasal polyps

Topical corticosteroids effective for nasal polyps Topical corticosteroids effective for nasal polyps | Cochrane Primary Care Trusted evidence. Informed decisions. Better health. Enter terms Topical corticosteroids effective for nasal polyps Cochrane Trusted evidence. Informed decisions. Better health. Copyright © 2019 The Cochrane Collaboration | | We use cookies to improve your experience on our site.

2013 Cochrane PEARLS

102. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part II) (Full text)

at Annual Meeting, the European Society of Intensive Care Medicine (EISCM) (co-chair of Corticosteroid Guideline in collaboration with SCCM), and the Korean Society of Critical Care Medicine (co-director and speaker at Multiprofessional Critical Care Board Review Course). He has spoken on the topic of corticosteroid use in critical illness and specifically in sepsis at the International Symposium in Critical and Emergency Medicine in March 2017. Dr. Annane has been involved with research relating (...) Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part II) Guidelines for the Diagnosis and Management of Critical Illn... : Critical Care Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me

2018 Society of Critical Care Medicine

103. Corticosteroids Provide Better Postoperative Endodontic Pain Relief Compared to Placebo (CAT#3350)

Corticosteroids Provide Better Postoperative Endodontic Pain Relief Compared to Placebo (CAT#3350) UTCAT3350, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Corticosteroids Provide Better Postoperative Endodontic Pain Relief Compared to Placebo Clinical Question In patients receiving non-surgical endodontic therapy, do corticosteroids provide better postoperative endodontic pain relief compared to placebo? Clinical (...) and dosages of corticosteroids produced different levels of analgesic efficacy. The three main types of corticosteroids studied in this article were prednisolone, dexamethasone, and betamethasone. At 6 hours, prednisolone had a more significant effect on pain relief than the other two drugs due to faster onset. It is speculated that this was because prednisolone has a shorter half-life and diffuses across the cell membrane at a faster rate to affect gene transcription. Applicability This topic

2018 UTHSCSA Dental School CAT Library

104. Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma

Appendix B. List of Excluded Studies Appendix C. Study Characteristics Appendix D. Risk of Bias Assessment Appendix E. Strength of Evidence Assessments Appendix F. Forest Plots ES-1 Evidence Summary Objectives and Rationale for the Review This report summarizes a systematic review of intermittent inhaled corticosteroids and long- acting muscarinic antagonists for asthma, and identifies needs for future research. This was one of the six high priority topics within asthma identified by a National Heart (...) Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma Comparative Effectiveness Review Number 194 Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma e Comparative Effectiveness Review Number 194 Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857

2018 Effective Health Care Program (AHRQ)

105. Corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

via small openings (ostia). Rhinosinusitis occurs when the mucosal lining of the paranasal sinuses becomes inflamed and infected. Typical symptoms include fever, pain and tenderness over the infected area, together with a blocked or runny nose. Acute rhinosinusitis frequently resolves spontaneously with little or no treatment, but it can become chronic. 2.2 The symptoms of chronic rhinosinusitis are usually managed with analgesics, antibiotics, topical corticosteroids or nasal irrigation (...) . Foam dressings, nasal packing and middle meatal spacers are sometimes used after surgery to try to maintain sinus patency. 3 3 The procedure The procedure 3.1 Inserting a corticosteroid-eluting bioabsorbable stent or spacer for paranasal sinus disease aims to deliver topical corticosteroid after surgery and to maintain patency of the newly created drainage system. It is usually done with the patient under general anaesthesia, during functional endoscopic sinus surgery, which may include balloon

2016 National Institute for Health and Clinical Excellence - Interventional Procedures

106. Topical Timolol Maleate 0.5% for Infantile Hemangioma: Its Effectiveness Compared to Ultrapotent Topical Corticosteroids - A Single-Center Experience of 278 Cases. (Full text)

Topical Timolol Maleate 0.5% for Infantile Hemangioma: Its Effectiveness Compared to Ultrapotent Topical Corticosteroids - A Single-Center Experience of 278 Cases. Infantile hemangioma (IH) may have implications on parental distress and cosmetic disfigurement. To date, ultrapotent corticosteroids are used as a treatment of choice for superficial IH. However, due to their side effects and sometimes lack of IH regression, it is necessary to find alternative topical therapies. Timolol maleate 0.5 (...) % solution and gel are nonselective β-blockers that could inhibit proliferation and trigger regression of IH.To evaluate the efficacy of topical ultrapotent corticosteroids and timolol maleate 0.5% solution and gel for superficial IH.The study design was prospective. Two hundred and seventy-eight patients diagnosed as having superficial IH were enrolled from the outpatient clinic of the Department of Dermatology and Venereology, Dr. Sardjito Hospital, Yogyakarta, Indonesia, from January 2009 to December

2016 Dermatology

107. A Randomized, Split-Face, Controlled, Double-Blind, Single-Center Clinical Study: Transient Addition of a Topical Corticosteroid to a Topical Retinoid in Acne Patients to Reduce Initial Irritation. (PubMed)

A Randomized, Split-Face, Controlled, Double-Blind, Single-Center Clinical Study: Transient Addition of a Topical Corticosteroid to a Topical Retinoid in Acne Patients to Reduce Initial Irritation. 27787887 2018 08 06 2018 08 06 1365-2133 177 2 2017 08 The British journal of dermatology Br. J. Dermatol. A randomized, split-face, controlled, double-blind, single-centre clinical study: transient addition of a topical corticosteroid to a topical retinoid in patients with acne to reduce initial

2016 British Journal of Dermatology Controlled trial quality: uncertain

108. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience. (PubMed)

Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience. Calcineurin inhibitors are alternatives to corticosteroid for treatment of atopic dermatitis.We sought to compare the beneficial effects and adverse events associated with these therapies in treating patients with atopic dermatitis.Four databases were searched for randomized clinical trials comparing topical (...) calcineurin inhibitors versus corticosteroids in children and adults. Methodological quality was evaluated to assess bias risk. Clinical outcome and costs were compared.Twelve independent randomized clinical trials comparing calcineurin inhibitors (n = 3492) versus corticosteroids (n = 3462) were identified. Calcineurin inhibitors and corticosteroids had similar rates of improvement of dermatitis (81% vs 71%; risk ratio [RR] 1.18; 95% confidence interval [CI] 1.04-1.34; P = .01) and treatment success (72

2016 Journal of the American Academy of Dermatology

109. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. (Full text)

Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. Many clinicians have concerns about the safety of atopic dermatitis (AD) treatments, particularly in children requiring long-term daily maintenance therapy. Topical corticosteroids (TCS) have been widely used for >5 decades. Long-term TCS monotherapy has been associated with adverse cutaneous effects including atrophy, rebound flares (...) , and increased percutaneous absorption with potential for adverse systemic effects. Topical calcineurin inhibitors (TCIs), tacrolimus and pimecrolimus, available for 1-2 decades, are not associated with atrophy or increased percutaneous absorption after prolonged use and have much lower potential for systemic effects. However, since 2006 TCIs have carried a controversial Boxed Warning based on a theoretical risk of malignancy (eg, skin and lymphoma) that has limited TCI use for standard-of-care maintenance

2016 BMC pediatrics

110. Topical Photodynamic therapy

AK when compared in a randomized clinical trial. 48 Treatment induced erythema was reduced, with further reduction if a superpotent topical corticosteroid is applied just before and after PDT. Another centre has proposed ‘temperature-modulated PDT’ where sustained clearance of 90% of 724 AK at 1 year was achieved by warming the skin during 1 hour Levulan ALA incubation. 49 4. Fluorescent diagnosis The detection of skin surface fluorescence, visible following application of ALA and MAL, can (...) Topical Photodynamic therapy EDF Guidelines Office to Professor Dr. Nast: Martin Dittmann, Klinik für Dermatologie, Venerologie und Allergologie, Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany phone: +49 30 450 618 313, fax: +49 30 450 518 977, e-mail: martin.dittmann@charite.de European Dermatology Forum Guidelines on Topical Photodynamic Therapy Updated version – 2019 Expiry date: 08/2022 European Dermatology Forum Guidelines on Topical

2019 European Dermatology Forum

111. High-dose inhaled corticosteroids in asthma

High-dose inhaled corticosteroids in asthma Asthma: medicines safety priorities Asthma: medicines safety priorities Key therapeutic topic Published: 15 January 2015 nice.org.uk/guidance/ktt5 pathways K Ke ey points y points Inhaled corticosteroids (ICS) are the first-choice regular preventer therapy for adults, young people and children with asthma. When long-acting beta agonists (LABAs) are prescribed for people with asthma, they should be prescribed with an ICS. LABAs should not be used (...) . The recommendations on pharmacological treatment are principally aimed at people whose asthma is newly diagnosed or uncontrolled on their current treatment. Where the recommendations represent a change from clinical practice, people whose asthma is well controlled should not have their treatment changed purely to follow guidance. The NICE guideline recommends low-dose or paediatric low-dose inhaled corticosteroids (ICS) as first-line maintenance therapy for adults and children aged 5 and over who have asthma

2015 National Institute for Health and Clinical Excellence - Advice

112. A retrospective analysis of pediatric patients with lichen sclerosus treated with a standard protocol of class I topical corticosteroid and topical calcineurin inhibitor. (PubMed)

A retrospective analysis of pediatric patients with lichen sclerosus treated with a standard protocol of class I topical corticosteroid and topical calcineurin inhibitor. Lichen sclerosus (LS) is a chronic, inflammatory condition of the skin, affecting primarily the anogenital region potentially leading to changes in vaginal architecture and vulvar squamous cell carcinoma. Current recommended treatment for LS is high-potency corticosteroids. Calcineurin inhibitors may also have a role.The (...) objective of this study is to introduce a treatment regimen involving clobetasol to induce remission, then tacrolimus to maintain remission in pediatric females with LS.As a retrospective case series, we report 14 pediatric females between 2 and 10 years of age with LS treated with clobetasol 0.05% topical ointment and systematically bridged to tacrolimus 0.1% topical ointment. For each patient, gender, age at disease onset, and clinical symptoms and features were noted. Time in weeks to 75% clearance

2015 Journal of Dermatological Treatment

113. Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata

Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata (COLA) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02350023 Recruitment Status : Completed First Posted : January 29, 2015 Last Update Posted

2015 Clinical Trials

114. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I)

): Moderator at Annual Meeting, the European Society of Intensive Care Medicine (EISCM) (co-chair of Corticosteroid Guideline in collaboration with SCCM), and the Korean Society of Critical Care Medicine (co-director and speaker at Multiprofessional Critical Care Board Review Course). He has spoken on the topic of corticosteroid use in critical illness and specifically in sepsis at the International Symposium in Critical and Emergency Medicine in March 2017. Dr. Arlt participates in the Society (...) Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I) Guidelines for the Diagnosis and Management of Critical Illn... : Critical Care Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me

2017 Society of Critical Care Medicine

115. Antenatal Corticosteroid Therapy for Fetal Maturation

corticosteroids use for infants born before 34 weeks of gestation and timing of corticosteroids in relation to delivery will support quality improvement efforts to optimize appropriate and timely antenatal corticosteroid administration. For More Information The American College of Obstetricians and Gynecologists has identified additional resources on topics related to this document that may be helpful for ob-gyns, other health care providers, and patients. You may view these resources at . These resources (...) Antenatal Corticosteroid Therapy for Fetal Maturation Antenatal Corticosteroid Therapy for Fetal Maturation - ACOG Menu ▼ Antenatal Corticosteroid Therapy for Fetal Maturation Page Navigation ▼ INTERIM UPDATE A correction was published in November 2017 for this title. Click to view the correction. Number 713, August 2017 (Replaces Committee Opinion No. 677, October 2016) (Reaffirmed 2018) Committee on Obstetric Practice This Committee Opinion was developed by the American College

2017 American College of Obstetricians and Gynecologists

116. Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects

Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects - GOV.UK GOV.UK uses cookies to make the site simpler. Search Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects Coadministration of a corticosteroid with an HIV-treatment-boosting agent may increase the risk of adrenal (...) suppression due to a pharmacokinetic interaction. Published 14 December 2016 From: Therapeutic area: , , , , , , Contents Advice for healthcare professionals: all clinicians who may prescribe or administer steroids to patients with HIV should be aware that concomitant use of a corticosteroid metabolised by cytochrome P450 3A (CYP3A) and a HIV-treatment-boosting agent may increase the risk of systemic corticosteroid-related adverse effects although these reactions are rarely reported, there is potential

2017 MHRA Drug Safety Update

117. Moisturisers improve eczema symptoms and lessen the need for corticosteroids

score, mean difference [MD] -2.42 (95% confidence interval [CI] -4.55 to -0.28; three studies, 276 participants). However, the change was not considered clinically significant. Fewer people using moisturisers had flares, 27% compared to 67% not using moisturisers over six month follow up (risk ratio [RR] 0.40, 95% CI 0.23 to 0.70; two studies, 87 participants). Time between flares was prolonged with moisturisers (median of 180 versus 30 days). Less topical corticosteroids were needed for people (...) to the SCORAD score, mean difference [MD] -2.42 (95% confidence interval [CI] -4.55 to -0.28; three studies, 276 participants). However, the change was not considered clinically significant. Fewer people using moisturisers had flares, 27% compared to 67% not using moisturisers over six month follow up (risk ratio [RR] 0.40, 95% CI 0.23 to 0.70; two studies, 87 participants). Time between flares was prolonged with moisturisers (median of 180 versus 30 days). Less topical corticosteroids were needed

2019 NIHR Dissemination Centre

118. Corticosteroid injections provide only short term relief for rotator cuff disorders

the widespread use of corticosteroid injections, past trials have had mixed findings and their use continues to be debated. The last review on the topic was conducted in 2010, and since then four new trials have been published. What did this study do? This systematic review and meta-analysis identified 11 randomised controlled trials including 726 adults with rotator cuff disorders. One of the trials compared corticosteroid injection with placebo injection of salt water, and the remaining trials compared (...) to treat pain. Despite the widespread use of corticosteroid injections, past trials have had mixed findings and their use continues to be debated. The last review on the topic was conducted in 2010, and since then four new trials have been published. What did this study do? This systematic review and meta-analysis identified 11 randomised controlled trials including 726 adults with rotator cuff disorders. One of the trials compared corticosteroid injection with placebo injection of salt water

2019 NIHR Dissemination Centre

119. Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

of corticosteroids. Recently, it has also been reported after local administration of corticosteroids via inhaled and intranasal, epidural, intra-articular, topical dermal, and periocular routes. Published 15 August 2017 From: Therapeutic area: , , Contents Advice for healthcare professionals: advise patients to report any blurred vision or other visual disturbances during corticosteroid treatment consider referral to an ophthalmologist for evaluation of possible causes if a patient presents with vision problems (...) are thought to be associated with the effect of cortisol on the eye. CSCR has recently also been described after local administration of corticosteroids via inhaled and intranasal, epidural, intra-articular, topical dermal, and periocular routes. It is a rare side effect that occurs with all formulations. Although blurred vision is a symptom of CSCR, it is also an established side effect of steroid treatment. The causes of blurred vision are various and can also include cataract and glaucoma. Inform

2017 MHRA Drug Safety Update

120. Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone

: Treatment Official Title: Corticosteroid(CS) Injections for the Treatment of Common Upper Extremity Pathologies, With or Without Lidocaine Estimated Study Start Date : March 2019 Estimated Primary Completion Date : August 2021 Estimated Study Completion Date : August 2021 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Treatment Group (corticosteroid injection plus lidocaine) Treatment (...) Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Corticosteroid(CS) + Lido or Corticosteroid(CS

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>